Sarepta Therapeutics, Inc.
EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
Last updated:
Abstract:
Antisense oligomers complementary to a selected target site in the human dystrophin gene to induce exon 52 skipping are described.
Status:
Application
Type:
Utility
Filling date:
24 Jul 2020
Issue date:
13 May 2021